{"name":"KAI Pharmaceuticals","slug":"kai-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"KAI-9803","genericName":"KAI-9803","slug":"kai-9803","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"KAI-9803","genericName":"KAI-9803","slug":"kai-9803","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBEMDhMeTkyalZiZ0V3bU5LZEVFaHFPUVRMcWNlckN0TmFvY24tTkduQVFlbG03cFpvUnNZaXphOGVHdDJBclNfazI4OGhlRlltQWlXb28xdGNoMERiN0U1NlVqd3VWYkp0TVlJZ1VjZ2daVV9O?oc=5","date":"2026-01-28","type":"pipeline","source":"understandingai.org","summary":"An unlikely ally for open-source protein-folding models: Big Pharma - understandingai.org","headline":"An unlikely ally for open-source protein-folding models: Big Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9EMm5qRGw2aEZhak9YVkI0WWl4eFBpeUtJUG9meWJzUm5PVU92dk9aeFl4ZldOcm5NTVlHTU1ybkZQOU5rQXZNQWhWeDlNYjhKMy0zRDFLUVRKSGQyVXppNG1VNDIzdGExRVRLLVBaTXVwZmxm?oc=5","date":"2026-01-13","type":"pipeline","source":"bain.com","summary":"M&A in Pharmaceuticals: Bigger, Bolder, and Far More Strategic - bain.com","headline":"M&A in Pharmaceuticals: Bigger, Bolder, and Far More Strategic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxQVGFUSEpxTE0wSjE1TWZlcVNaclVaWFB0bXpQYVZpeFZLdEpwYUpBVEk4NVRoRkpFYU50cm15enpLZU56NXR6QklNdE5mUkVtZ203UHQxRmtWOXlHRzNOdF9ZSGRiVENIQ0hoblE3RUhaNkVnT0pPd0tTV2U4enNtdUpYRXVYRWtOcjNQUUdHS3Q3M0NHS19Yem5ONkVGVndPMWI3am1vSlZHUmJzamJ0NWFpRDQ3UTFGRUJ5b0tSeDlKb0l3VXZBTUtyVXhnV0xaQVRQN0xMYkJqNEJiaTJpVWVwem9SakhLSnYwaXN5WlJUT0o4VEZTZjJSOHlfQzU3bmluMEVZZ1lfUWE0Z015OXJrZlV1Y3ZaQjlrWEw1VmVQVGZ2M2c2a01JMnQ4Mlpxcl91UEdWUl8xdUk?oc=5","date":"2025-11-04","type":"trial","source":"globenewswire.com","summary":"Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 - globenewswire.com","headline":"Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP R","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPQ1l6WDVhS09LRkFaSXhOUWZEaGUxdkFZVDdsRl9QLXlXOWZSRUtoRkpvTmtweV8wRklDYlRFSlNkNWlLNUVzRXJhdl9LX3lSS2FCcjJmNmFTNkhGekt1Tk40RmVWSlM0cURjTl94c3dpSzFVNXgxd0xsN1RnWE9qQkdNZ2kyVnhVSVhYOEdBOXNXUEJp?oc=5","date":"2025-10-15","type":"pipeline","source":"Pharmaceutical Executive","summary":"Roundup: Capital Flows into Pharma with Funding Rounds and Loan Facilities - Pharmaceutical Executive","headline":"Roundup: Capital Flows into Pharma with Funding Rounds and Loan Facilities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBDOWRDOHVsQUFFczFHZkFnRi1ILW85SmxiX29PQkhicjNYT3NwMDlacXFYM2MxS29TWTVzcVAxODZxb21ncDZYcHNkTURESUxiMnRV?oc=5","date":"2025-10-14","type":"trial","source":"FirstWord Pharma","summary":"Kailera brings in $600M to kick off global Phase III programme for obesity drug - FirstWord Pharma","headline":"Kailera brings in $600M to kick off global Phase III programme for obesity drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPUzJqTUxZYXFOb3ItanpxZl9qeDViUThzR2FGbFFFY3U2dDl4X1pOWWZ3T0s0M25iLTFZck9UazdFaGZMN3pOai1aYkVTNFVGTzI0amppS1lzYzFKdFZ5X2xpUHN0Si1oZE9SNkFNNWJ6NUJmZDBQSV9ONlZXYkx3OFlaeW1pTDFBV2FxOS02VzNSQ0V6T0VTbmxza3g?oc=5","date":"2025-10-14","type":"pipeline","source":"BioPharma Dive","summary":"Kailera nets $600M more to advance Zepbound-like obesity drug - BioPharma Dive","headline":"Kailera nets $600M more to advance Zepbound-like obesity drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNSW9NOEMtampRUzlhSHpyeGNMTGNUekVCZnFpNktPZm05NUgwbkg5MF9QcktrYkdxMFNCMEItV0UydW1wVTVxanVXWElteVFUVDZqZXMzcVJTc1VjWVpuclFnTU1tenpaaFBpVUd1ZlVJWEJqeDRkMnVrY1JnNHpFRzFzbEVsQ0hoXzdtag?oc=5","date":"2025-10-14","type":"trial","source":"pharmaphorum","summary":"$600m round will help Kailera push obesity drug into phase 3 - pharmaphorum","headline":"$600m round will help Kailera push obesity drug into phase 3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPd2JINDlQOWZtQ19IeTVmbFBMNFN2c1U4bm1hOThqYXZsMkN6bEk3VkpLVkpwQXVQdGd1ZThBTXI4bHA2dWpCS2RfYno5Vm9pdmNnSExLSURyS2pWTDhoZWI0bERIbHk2dXU3cjJPUmJVUHpwclpNYlBGS3ZBQVduT1g5QlhoZllOX0VSN3dGaERnd2hXMnZybTVabldwYWgzbkJWZkt5WWZab0RVWFVMWEZqeWJaVk0?oc=5","date":"2025-09-30","type":"pipeline","source":"European Pharmaceutical Review","summary":"Kai Beckmann to take over from Belén Garijo as Merck CEO | News - European Pharmaceutical Review","headline":"Kai Beckmann to take over from Belén Garijo as Merck CEO | News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPcUpDVFh0a2xXTno4dHZqc21pUjhLOVljZWpTeGUtY1pUc3VlVVZfTFVPUlctRFU1UDl2NHZETHMzN2FjN3RCY29hRzdYWGM0cEx3dXRFdjIzbmVrVDU2Unl4ZV92UWdkdWZUd0tnYkZMTlFnbGpmTDNLNXpGMnpTd0htZWVFNUtrX3MwN0VkZTJ5MFhRbVNiTzJEN0Zvdy1PWjQ1aFR0UkhiQlZUd3pjWndrMmI?oc=5","date":"2025-09-25","type":"pipeline","source":"Fierce Pharma","summary":"Merck KGaA, grappling with geopolitical tensions, ⁠reveals CEO transition - Fierce Pharma","headline":"Merck KGaA, grappling with geopolitical tensions, ⁠reveals CEO transition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQT0tIRUVDLWwtX0xwcHBTRUs4R3ZjZ01VYWhtQnFaR0JMQ3A5WDFBWnhhZndSLXBDdVlMWjBPYWZJV01KcVAxWVlSMWk3bW80NHQ2djEtMHljcFdaMW01T1pkQ3hHWmlOWGRFWjFabUoyOWZrWU1HMTBYVnBYSE0yNFdnYndicmJ2bGt2MS0yVndpbEotY2tLdS1ZV2I5bWR4blRrQ3RR?oc=5","date":"2025-08-05","type":"pipeline","source":"BioXconomy","summary":"Global pharma drug delivery market to reach $2.5bn by 2029 - BioXconomy","headline":"Global pharma drug delivery market to reach $2.5bn by 2029","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOLUhxa2ZpUXJHWXA0bXgwUnZQY1FfS002a0VXSDd6VUhkUDZlTy1kcDZhOFpwSE9UalNoeG5TQ2lwNVFBTkI1LTVjZkwyWGJHNS00a3ZVNHFnblVBMjQ2aVlMLW5RZFNlT08tb3dHUjVaVlhxX3ZPdzVBVzR2MjBsVlhONHpHODk2R3FSME5KQ1EzeUZFZS1fcWlzMW5WUWVVQzJzcHBMV21ab0t1TERjd281SmJ2bldCS2dDVjdFMS0ySlNtNjNvWlJYV3g?oc=5","date":"2025-04-07","type":"deal","source":"Microsoft Source","summary":"SkyCell and Microsoft Announce Collaboration to bring Copilot into Pharma Supply Chains - Microsoft Source","headline":"SkyCell and Microsoft Announce Collaboration to bring Copilot into Pharma Supply Chains","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE5JODVoS2pGVEJYS3g3akY1TlVvVkdaUUhRbDZrSlBfamFsMk9BakxiZkhWczBFcVVtQjkzb2loTXB4UVFnTTd5RV9UVGdEWjRzdjB1RV9VcGFOLURRcnQwMjY4YjlIelFvUTNzYjdPdVZPbGZHTklV?oc=5","date":"2024-02-01","type":"pipeline","source":"Pharmaceutical Technology","summary":"Pharmaceutical Technology Excellence Awards 2023: KAI Conversations - Pharmaceutical Technology","headline":"Pharmaceutical Technology Excellence Awards 2023: KAI Conversations","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}